Humacyte (HUMA) Current Assets (2020 - 2026)
Humacyte (HUMA) posted quarterly Current Assets of $63.6 million for Q1 2026, down 13.71% year-over-year from $73.7 million in Q1 2025, and down 6.19% quarter-over-quarter from $67.8 million in Q4 2025.
Humacyte (HUMA) Current Assets (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Current Assets for 7 consecutive years, with $63.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 13.71% year-over-year to $63.6 million; the TTM figure through Mar 2026 stood at $63.6 million (down 13.71% YoY), while the FY2025 annual figure was $67.8 million, up 41.66% from the prior year.
- Current Assets declined to $63.6 million in Q1 2026 per HUMA's latest filing, from $67.8 million in the prior quarter.
- Across five years, Current Assets topped out at $209.3 million in Q1 2022 and bottomed at $23.0 million in Q3 2024.
- Historically, Current Assets has averaged $103.2 million across 5 years, with a median of $96.1 million in 2024.
- Annual changes were most pronounced in 2022 — Current Assets jumped 41610.87% — and 2024, when it tumbled 77.63%.
- Humacyte's Current Assets stood at $154.2 million in 2022, then plunged by 46.0% to $83.3 million in 2023, then sank by 42.53% to $47.9 million in 2024, then surged by 41.66% to $67.8 million in 2025, then dropped by 6.19% to $63.6 million in 2026.
- Business Quant data shows HUMA's Current Assets at $63.6 million in Q1 2026, $67.8 million in Q4 2025, and $41.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Humacyte | 158.12 Mn | 158.12 Mn | -825,000.00 | 92.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 92.79 Mn |
| Mar 31, 2026 | 63.60 Mn |
| Dec 31, 2025 | 67.80 Mn |
| Sep 30, 2025 | 41.35 Mn |
| Jun 30, 2025 | 51.73 Mn |
| Mar 31, 2025 | 73.71 Mn |
| Dec 31, 2024 | 47.86 Mn |
| Sep 30, 2024 | 23.01 Mn |
| Jun 30, 2024 | 96.11 Mn |
| Mar 31, 2024 | 117.93 Mn |
| Dec 31, 2023 | 83.28 Mn |
| Sep 30, 2023 | 102.85 Mn |
| Jun 30, 2023 | 120.56 Mn |
| Mar 31, 2023 | 133.86 Mn |
| Dec 31, 2022 | 154.21 Mn |
| Sep 30, 2022 | 174.61 Mn |
| Jun 30, 2022 | 193.03 Mn |
| Mar 31, 2022 | 209.30 Mn |
| Dec 31, 2021 | 229.34 Mn |
| Sep 30, 2021 | 244.18 Mn |